Palmitoylethanolamide for horses suffering from chronic pain and/or inflammations
Horses often suffer from chronic pain states related to running, jumping or other movement- related disorders. Mostly either vetenarian analgesics or supplements are administered. The vetenarian analgesics have a clear drawback, namely various side effects, and most of the supplements are not scientifically well established as effective treatments.
Especially the use of corticosteroids and analgesics give rise to side effcts in horses wich can compromise their functions and quality of life. The body own analgesic and anti inflammatory agent palmitoylethanolamide can be succesfully applied to horses and horses suffering chronic pain and/ or inflammation. Many studies in various animals have proven the efficacy and safety of palmitoylethanolamide. The compound also has relevant efficacy in horses, as we will demonstrate in the following cases.
Racehorse suffering from scar and keloid, limping and immobile
A 8 year-old thoroughbred male chestnut racehorse had a large keloid, a kind of chronic inflammation, soft to the touch, in the palmar region of the metacarpal of the lower left-hand limb in a proximal position on the profound flexor tendon.
The horse had undergone an operation on the above-mentioned tendon 6 months previously for a serious traumatic lesion of the sheath.
The animal had a pronounced limp and was practically immobilized.
Treatment for 30 days administration of 2 gram each day of palmitoylethanolamide. This brought about a regression of the keloid by between 90 and 95%. The animal was able to recommence competitive activity.
Racehorse with tendon pathology
A 3-year-old female bay racehorse had a spheroidal formation the size of a lemon, of soft connective tissue in the latero-palmar region of the metacarpal of the left-hand front limb. The keloidal formation was connected to the profound flexor tendon. The tendon had been burnt about four months previously.
After treatment for 30 days with 2 gram each day of palmitoylethanolamide, the formation regressed completely and the functionality of the tendon was completely restored.
Racehorse with chronic flexor tendinitis
A 5-year-old male bay racehorse, had signs of recurrent, chronic tendon inflammation on the right-hand front profound flexor. Two years previously, the subject had undergone an operation, tendonectomy, for a lesion of the sheath, from which it had never fully recovered.
After treatment for 30 days with administration of 2 gram each day of pallmitoylethanolamide, the tendon pathology was clearly reduced.
After a further 30 days with the same treatment regime, the subject was completely cured with considerable benefit to its competitive performance.
Racehorse suffering from acute tendinitis
A 2 year-old thoroughbred male bay racehorse had acute inflammation of its tendon, a tendinitis of the right-hand front profound flexor. As a result of an operation performed for the reduction of tendonous oedema, the animal developed a considerable fibrotic reaction with the production of adhesions.
5 months after the operation, treatment was started with 2 gram each day of palmitoylethanolamide. After 30 days a considerable improvement was noted and the treatment was continued for a further 60 days.
After treatment for 90 days, the tendon pathology was perfectly cured and the adhesions previously found had completely regressed. The animal returned to competitive activity.
Palmitoylethanolamide for horses and pet animals
It is clear from these results described above, that palmitoylethanolamide can advantageously be used in the treatment of chronic inflammation and in chronic painstates in horses, such as tendonous pathology in horses, both when these conditions are acute and when they are chronic.
In the last horse described animal, the treatment with palmitoylethanolamide clearly was the only effective cure for tendonous pathology, which enabled the horse to return to competitive activity.
Palmitpylethanolamide has been tested in many different animal species, cats, dogs, including human, and in all clinical trials were palmitoylethanolamide was tested in pain or inflammation robust efficacy AND great safety has been documented. (see under for animal references)
Palmitoylethanolamide is about the most researched animal supplement and its evidence base is impressive. Over many mammal species we find the same efficacy and safety.
In the Netherlands nearly 100 King Charles Spaniels suffering from neuralgic pains and inflammation of the eyes have been succesfully treated, without side effects.
The treatment of animals with palmitoylethanolamide, results comparable to treatments with cortisones, with the substantial advantage that it does not have the serious side effects typical of these corticosteroids. Source:http://www.patentstorm.us/patents/6548550/description.html
Palmitoylethanolamide: dose recommendations for the treatment of horses
The recommended dose based on a number of trials in animals is 10-30 mg for each kg bodyweight.
For the sake of simplicity a step-in dose could be 2-3 gram each day, in two gifts of 1-1.5 gram each day, or in one gift of 2-3 gram. It can be easily obtained by using the PEA powder from PeaPure capsules. These capsules are easy to open and the content can be sprinkled over horse food.
Palmitoylethanolamide in dogs and cat
Vet J. 2012 Mar;191(3):377-82. Epub 2011 May 20.
Effects of palmitoylethanolamide on the cutaneous allergic inflammatory response in Ascaris hypersensitive Beagle dogs.
Cerrato S, Brazis P, Della Valle MF, Miolo A, Petrosino S, Marzo VD, Puigdemont A.
Vet Dermatol. 2001 Feb;12(1):29-39.
Clinical and histological evaluation of an analogue of palmitoylethanolamide, PLR 120 (comicronized Palmidrol INN) in cats with eosinophilic granuloma and eosinophilic plaque: a pilot study.
Scarampella F, Abramo F, Noli C.
 Marini I, Bartolucci ML, Bortolotti F, Gatto MR, Bonetti GA. | Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain. | J Orofac Pain. | 2012 Spring;26(2):99-104.
 Skaper SD. | Conference report: 1st workshop on "palmitoylethanolamide: biochemistry, pharmacology and therapeutic use of a pleiotropic anti-inflammatory lipid mediator". | CNS Neurol Disord Drug Targets. | 2012 May;11(3):191.
 D'Agostino G, Russo R, Avagliano C, Cristiano C, Meli R, Calignano A. | Palmitoylethanolamide protects against the amyloid-?25-35-induced learning and memory impairment in mice, an experimental model of Alzheimer disease. | Neuropsychopharmacology. | 2012 Jun;37(7):1784-92. doi: 10.1038/npp.2012.25. Epub 2012 Mar 14.
 Truini A, Biasiotta A, Di Stefano G, La Cesa S, Leone C, Cartoni C, Federico V, Petrucci MT, Cruccu G. | Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy. | CNS Neurol Disord Drug Targets. | 2011 Dec;10(8):916-20.
 Conigliaro R, Drago V, Foster PS, Schievano C, Di Marzo V. | Use of palmitoylethanolamide in the entrapment neuropathy of the median in the wrist. | Minerva Med. | 2011 Apr;102(2):141-7.